ERAP2 and rheumatoid arthritis: ERAP2 can increase the expression and release of IL-1β, IL-18, and Caspase-1, and also the aggregation of inflammatory vesicles in PBMCs of RA patients, which may eventually lead to the development of pyroptosis.